Pantoprazole
Pantoprazole is a proton pump inhibitor used in adults and children for gastro-oesophageal reflux disease, peptic ulcer disease, NSAID-induced ulcer prophylaxis and Zollinger-Ellison syndrome. It is often preferred when CYP2C19 drug interactions are a concern.
- Chemical formula
- C16H15F2N3O4S
- CAS number
- 102625-70-7
- ATC code
- A02BC02
- Molecular weight
- 383.37 g/mol
- Drug class
- Proton pump inhibitor
- Also known as
- BY-1023, Pantoprazol
What is it?
Pantoprazole is a substituted benzimidazole proton pump inhibitor approved for clinical use in 1994. It is supplied as oral delayed-release tablets, oral suspension and parenteral solution. Pantoprazole is dispensed both with and without prescription depending on dose and country. It is part of the World Health Organization List of Essential Medicines and is widely used in hospital and outpatient settings for acid-related disorders.
Mechanism of action
Pantoprazole is a substituted benzimidazole prodrug activated in the acidic environment of the gastric parietal cell, where it irreversibly inhibits the H+/K+-ATPase enzyme — the proton pump responsible for the final step in gastric acid secretion. Acid secretion gradually returns after discontinuation as new pumps are synthesised. Compared with omeprazole and esomeprazole, pantoprazole is a weaker inhibitor of CYP2C19 at therapeutic doses.
Pharmacokinetics
Pantoprazole is absorbed orally as enteric-coated formulations to protect against gastric acid degradation, with peak plasma concentrations reached after two to three hours. Bioavailability is approximately 77%, higher than for omeprazole, and is not significantly affected by food. Plasma protein binding is approximately 98%. The drug is metabolised by CYP2C19 (predominantly) and CYP3A4 to inactive metabolites. The terminal half-life is approximately one hour, but the antisecretory effect lasts much longer.
Indications
Pantoprazole is approved in adults and children for the treatment of gastro-oesophageal reflux disease, including erosive oesophagitis healing and maintenance, peptic ulcer disease, prevention of NSAID-induced ulcers, Zollinger-Ellison syndrome and as part of triple-therapy regimens for Helicobacter pylori eradication. According to clinical guidelines, the lowest effective dose for the shortest necessary duration should be used, with periodic reassessment of long-term therapy.
Safety profile
Common adverse effects include headache, gastrointestinal symptoms and dizziness. Long-term use has been associated with potential reductions in vitamin B12 and magnesium absorption, an increased risk of bone fractures, kidney injury and possible enteric infections including Clostridioides difficile. Pantoprazole has fewer clinically relevant CYP2C19 interactions than omeprazole, making it the preferred proton pump inhibitor in patients on clopidogrel. According to the prescribing information, long-term therapy should be regularly reassessed.
Products containing this ingredient
Frequently asked questions
Why is pantoprazole preferred in patients on clopidogrel? ▾
Pantoprazole is a weaker inhibitor of CYP2C19 than omeprazole and esomeprazole at therapeutic doses, so it has less effect on the activation of the antiplatelet prodrug clopidogrel. According to several regulatory communications and clinical guidelines, when a proton pump inhibitor is needed in a patient on clopidogrel, pantoprazole is generally preferred over omeprazole or esomeprazole. The choice should be made by the prescriber.
How is pantoprazole different from omeprazole? ▾
Both are substituted benzimidazole proton pump inhibitors with similar acid-suppressive efficacy at equivalent doses. Pantoprazole has higher oral bioavailability (around 77% vs 30-40%), a more food-independent absorption and weaker CYP2C19 inhibition than omeprazole. Choice between the two depends on the clinical context, drug interactions and the prescriber's judgement, with both supported by international guidelines.
When should pantoprazole be taken? ▾
Pantoprazole is most effective when taken approximately 30 to 60 minutes before a meal, ideally before breakfast, because the proton pumps are most active during meals. According to the prescribing information, tablets should be swallowed whole with water and not crushed or chewed, because the enteric coating protects the active drug from gastric acid degradation. Oral suspension formulations have specific reconstitution instructions.
Can pantoprazole be taken long-term? ▾
Pantoprazole is commonly used for prolonged periods in chronic GORD, Barrett's oesophagus and peptic ulcer prophylaxis with NSAIDs. Long-term use has been associated with potential reductions in vitamin B12 and magnesium absorption, an increased risk of bone fractures and possible enteric infections. According to international guidelines, long-term proton pump inhibitor therapy should be regularly reassessed, with the lowest effective dose used.
What are the main contraindications for pantoprazole? ▾
Pantoprazole is contraindicated in known hypersensitivity to pantoprazole or substituted benzimidazoles, and in concurrent use with rilpivirine. Caution is required in severe hepatic impairment, in long-term use with monitoring of magnesium and bone density, and during pregnancy and breastfeeding. According to the prescribing information, the medical history must be reviewed by a clinician before any prescription.
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.